focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ProPhotonix Introduces the Cobra Cure FX3

6 Sep 2016 07:00

RNS Number : 8830I
ProPhotonix Limited
06 September 2016
 

 

September 6, 2016

ProPhotonix Limited

("ProPhotonix" or "the Company")

ProPhotonix extends COBRA CURE FX Series with 16 W/cm2 Higher Power Fan-cooled UV Curing System

Compact, UV LED Solution featuring an innovative configurable design, stackable and other unique features

 

ProPhotonix Limited, (London Stock Exchange - AIM: PPIX; OTC: STKR), a high technology designer and manufacturer of LED illumination systems and laser diode modules, announces the COBRA Cure FX3, an extension to its UV LED Curing systems. The COBRA Cure FX3 is the highest intensity air cooled product in ProPhotonix' UV family.

 

The COBRA Cure FX3 follows from the previously announced COBRA Cure FX1, which produces a uniform line with a peak irradiance of 6 W/cm2 and peak energy density (dose) of 5 J/cm2 and the COBRA Cure FX2, which produces a uniform line with a peak irradiance of 8.4 W/cm2 and energy densities up to 17.5 J/cm2. The COBRA Cure FX3 delivers best-in-class intensities up to 16 W/cm2 and energy densities up to 42 J/cm2.

 

The COBRA Cure FX3 is scalable without any drop in intensity from module to module ensuring consistent edge-to-edge illumination. The design is unique incorporating surge protection, LED segment control, and power control between 5% and 100%. The control of each LED segment is designed to monitor and drive each LED segment providing consistent intensity control across the entire illumination area. Wavelength options include 365nm, 385nm, 395nm, and 405nm configurations as well as integrated multi-wavelength options.

 

Tim Losik, CEO and President of ProPhotonix, said "ProPhotonix (IRL) Limited has been a pioneer in LED technology since 1994 and a provider of UV LED solutions since 2006. As an early adopter of LED chip-on-board technology, ProPhotonix provides high intensity illumination across all LED wavelengths - including UV. The FX3 adds to our broad range of UV LED products providing more illumination options for our customers. Estimates are that market demand for UV LED systems will grow at nearly 40% per annum through 2019 to $500 million. We are uniquely positioned to significantly participate in this high growth market and deliver ongoing enhancements to our customers."

 

For more information about COBRA Cure FX3, visit www.prophotonix.com/products/UV-Solutions.

 

Contact:

 

ProPhotonix Limited

Simon Stanley, Managing Director, Ireland

 

Sales

 

+353-21500-01300

 

sales@prophotonix.com

 

About ProPhotonix

ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com

 

Cautionary Statement 

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALTMPTMBJMBIF
Date   Source Headline
13th Aug 20127:00 amRNSHalf Yearly Report
25th May 20122:30 pmRNSGrant of Options (Replacement)
17th May 20127:00 amRNSAGM Statement
1st May 20124:21 pmRNSPosting of Annual Report and Accounts
5th Apr 20127:00 amRNSAppointment of Three New Distribution Partners
26th Mar 20127:00 amRNSGrant of Options
19th Mar 20127:00 amRNSAppointment of Joint Broker
1st Mar 20127:00 amRNSFinal Results
1st Feb 20127:00 amRNSChange of Name of Nominated Adviser and Broker
19th Jan 20127:00 amRNSTrading Update and New Product Launch
27th Oct 20117:00 amRNS3rd Quarter Results
28th Jul 20117:00 amRNSHalf Yearly Report
20th Jul 20117:00 amRNSNotice of Results
13th Jul 20117:00 amRNSIssue of Equity
26th May 20111:51 pmRNSDirector/PDMR Shareholding
24th May 20115:09 pmRNSDirector/PDMR Shareholding
10th May 20117:00 amRNSChange of Adviser
4th May 20117:00 amRNS1st Quarter Results
19th Apr 20115:28 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.